Table 1.
Interviewed (n = 20) | Not interviewed (n = 18) | N (%) | |
---|---|---|---|
Age, mean ± SD | 67 (7.5) | 64 (10.1) | |
Stage at diagnosis | |||
Stage 1 | 1 | 2 | 3 (7.9) |
Stage 2 | 0 | 1 | 1 (2.6) |
Stage 3 | 16 | 15 | 31 (81.6) |
Stage 4 | 3 | 0 | 3 (7.9) |
Missing | 0 | 0 | 0 |
Histology at diagnosis | |||
Serous | 15 | 16 | 31 (81.6) |
Endometrioid | 1 | 0 | 1 (2.6) |
Clear cell | 1 | 1 | 2 (5.3) |
Mucinous | 0 | 1 | 1 (2.6) |
Adenocarcinoma NOS | 2 | 0 | 2 (5.3) |
Carcinosarcoma | 1 | 0 | 1 (2.6) |
Previous surgery | |||
Total anterior hysterectomy | 18 | 14 | 32 (82.5) |
Bilateral-salpingo-oophorectomy | 17 | 12 | 29 (76.3) |
Omentectomy | 15 | 14 | 29 (76.3) |
Re-laparotomy | 4 | 4 | 8 (20.5) |
Chemotherapy at BO admission | |||
Total number | 12 | 13 | 25 (63.0) |
Platinum based | 7 | 7 | 14 (37.0) |
ECOG PS at BO admission | |||
0 | 1 | 0 | 1 (2.6) |
1 | 5 | 3 | 8 (21.1) |
2 | 7 | 5 | 12 (31.6) |
3 | 3 | 4 | 7 (18.4) |
4 | 0 | 1 | 1 (2.6) |
Unknown | 4 | 5 | 9 (23.7) |
No statistical significant differences
ECOG PS Eastern Cooperative Oncology Group performance status